FDA OKs Medtronic's fluid-monitoring HF (heart failure) device:
This article was originally published in Clinica
Executive Summary
The US FDA has approved Medtronic's InSync Sentry cardiac resynchronisation therapy (CRT) defibrillator system, the first CRT device that can automatically alert clinicians to changes in fluid accumulation in the lungs and thoracic cavity. Most hospital admissions for heart failure (HF) are due to fluid accumulation in the thorax, which often goes undetected until the patient is critically ill. Such patients can require urgent treatment in hospital, posing a tremendous cost burden to healthcare systems. The InSync Sentry provides an early warning of worsening symptoms before hospitalisation is critical, allowing physicians to adjust patient treatment proactively. It monitors fluid status using a feature called OptiVol, which measures changes in intra-thoracic impedance, an indication of changing fluid volume. The device was released in Europe earlier this year and will be launched in the US early next year.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.